Press Releases 23andMe Holding Co.

Equities

ME

US90138Q1085

Real-time Estimate Cboe BZX Other stock markets 03:33:47 2024-05-08 pm EDT			5-day change	1st Jan Change
0.5 ^USD	+0.48%		-0.20%	-45.34%

Apr. 24	23andMe Holding Co. to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology Annual Meeting	CI
Apr. 23	Petros, Lemonaid Health Collaborate to Expand Stendra Availability	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case	Apr. 30	BU
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	Apr. 24	GL
23andMe announces CEO’s intention to pursue a potential take-private	Apr. 18	GL
23andMe announces CEO’s intention to pursue a potential take-private	Apr. 18	AQ
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024	Apr. 05	GL
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6	Mar. 20	GL
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6	Mar. 20	AQ
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago	Mar. 19	GL
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago	Mar. 19	AQ
23andMe Launches New Genetic Reports on Common Forms of Cancer	Mar. 06	GL
23andMe Launches New Genetic Reports on Common Forms of Cancer	Mar. 06	AQ
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024	Mar. 05	GL
23andMe Reports Third Quarter Fiscal 2024 Financial Results	Feb. 07	GL
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6	Jan. 31	GL
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6	Jan. 31	AQ
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay	Jan. 30	GL
23andMe to Report FY2024 Third Quarter Financial Results	Jan. 24	GL
23andMe to Report FY2024 Third Quarter Financial Results	Jan. 24	AQ
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts	Dec. 19	GL
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts	Dec. 19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

INTERVIEW - Anne Wojcicki, CEO of 23andMe: partnership with Amazon and cancer treatment results

July 13, 2023 at 02:26 pm EDT